No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
FOLD240719P11000
- 0.53
- 0.000.00%
15min DelayClose Jul 19 15:29 ET
0.53High0.50Low
0.50Open0.53Pre Close3 Volume0 Open Interest11.00Strike Price0.00Turnover0.00%IV-1.85%PremiumJul 19, 2024Expiry Date0.72Intrinsic Value100Multiplier-3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma19.40Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
TD Cowen analyst Ritu Baral maintains $Amicus Therapeutics(FOLD.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 47.6% and
Amicus Therapeutics(FOLD.US) Officer Sells US$61,029.28 in Common Stock
$Amicus Therapeutics(FOLD.US)$ Officer Campbell Bradley L sold 6,100 shares of common stock on Jul 5, 2024 at an average price of $10.0048 for a total value of $61,029.28.Source: Announcement What
Stifel Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
Stifel analyst Dae Gon Ha maintains $Amicus Therapeutics(FOLD.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 37.5% and a
Amicus Therapeutics(FOLD.US) Officer Sells US$14,002.94 in Common Stock
$Amicus Therapeutics(FOLD.US)$ Officer Campbell Bradley L sold 1,400 shares of common stock on Jul 1, 2024 at an average price of $10.0021 for a total value of $14,002.94.Source: Announcement What is
Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Investors in Amicus Therapeutics (NASDAQ:FOLD) From a Year Ago Are Still Down 19%, Even After 3.9% Gain This Past Week
Comments
» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
8
Despite Amicus Therapeutics' recent share price uptick and steady revenue growth, the market's high expectations are reflected in the share price fall over the past three years. The company's 3.2% total shareholder return over the last twelve months falls short of the market return.
Investors might overlook Amicus Therapeutics' below industry-level growth forecast, risking future disappointment if the P/S ratio falls in line with the growth outlook. Moderate P/S ratio poses a risk as weaker revenue outlook might lead to share price drop.
$Amicus Therapeutics(FOLD.US$ FDA approval 🚀🙏🏻
Read more